Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy)

NCT01663168 is registered in ClinicalTrials.gov with Justine Boles as lead sponsor.

NCT NCT01663168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01663168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy)
Lead sponsor
Justine Boles
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2011
Completion date
January 31, 2014
Enrollment
140 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis